Brain rejuvenation: an innovative approach to Huntington's disease therapy
Programme: Programme de recherche NAVIGATOR
Organisme(s) subventionnaire(s): Société Huntington du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2025 au 1 septembre 2027

Redefining PD pathophysiology mechanisms in the context of heterogeneous substantia nigra neuron subtypes
Programme: ASAP Collaborative Research Network
Organisme(s) subventionnaire(s): Michael J. Fox Foundation for Parkinson's Research
Type de financement: Subvention
Établissement tête: Northwestern University
Du 1 novembre 2024 au 31 octobre 2026

Development of a proprietary cysteamine formulation (SYN-001) responding to the clinical needs in Parkinson’s disease
Programme: Collaborative Projects on the Brain
Organisme(s) subventionnaire(s): Synucure Thérapeutique inc., Consortium québécois sur la découverte du médicament
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2024 au 30 juin 2026

Financements des 2 dernières années

Les effets de la cystéamine chez les patients souffrant de la maladie de Huntington : Analyse des données cliniques
Programme: Développement de la recherche (RFI)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2023 au 31 décembre 2023

Premier biomarqueur sanguin de la maladie de Parkinson : de la validation à la commercialisation
Programme: Projets de maturation technologique PSO – volet 2d
Organisme(s) subventionnaire(s): Fondation du CHU de Québec, Synucure Thérapeutique inc., Ministère de l'Économie et de l'Innovation
Type de financement: Subvention
Établissement tête: Université Laval
Du 14 septembre 2022 au 13 septembre 2024

Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 20 décembre 2021 au 19 décembre 2024

Redefining PD pathophysiology mechanisms in the context of teterogeneous substantia nigra neuron subtypes
Programme: Target Advancement Program
Organisme(s) subventionnaire(s): Northwestern University
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2021 au 31 octobre 2024

Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2020 au 31 mars 2025

Untangling tau contribution to cognitive impairments in Huntington’s disease.
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2019 au 31 mars 2024

Lucile Gentile, Stage postdoctoral en neurobiologie

Sonia Catalina Cerquera Cleves, Doctorat en neurosciences

Thyago Cardim Pires, Stage postdoctoral en neurobiologie

Christine Trabolsi, Doctorat en neurosciences

Joao Gabriel Bernardo Leandro, Doctorat en médecine moléculaire

Flavia Natale Alves Martins Borba, Doctorat en neurosciences

Eva Lepinay, Doctorat en neurosciences

Encadrements terminés dans les 5 dernières années

Alberto Siddu, Doctorat en neurobiologie

Giacomo Sciacca, Doctorat en neurobiologie

Héléna Denis, Maîtrise en neurobiologie - avec mémoire

Héléna Denis, Doctorat en neurobiologie

Shireen Salem, Doctorat en médecine moléculaire

Eva Lepinay, Maîtrise en neurosciences - avec mémoire

Publications des 5 dernières années

Vascular dysfunction in Huntington’s disease is located at the blood-CSF barrier and is rescued by sphingosine-1-phosphate receptor agonist 2025/05/05. Krzysztof Kucharz, Rana Soylu-Kucharz, Martine Saint-Pierre, Melanie Alpaugh, Filippa L. Qvist, Maria Björkqvist, Niels Henning Skotte, Francesca Cicchetti, Martin Lauritzen. DOI 10.1101/2025.04.30.650996

Healthy blood, healthy brain: a window into understanding and treating neurodegenerative diseases Journal of Neurology, 2024/06. Thyago R. Cardim-Pires, Aurélie de Rus Jacquet, Francesca Cicchetti. DOI 10.1007/s00415-024-12337-w

Tau: a biomarker of Huntington’s disease Molecular Psychiatry, 2023/10. Eva Lepinay, Francesca Cicchetti. DOI 10.1038/s41380-023-02230-9

Passive immunization against phosphorylated tau improves features of Huntington's disease pathology Molecular Therapy, 2022/04. Melanie Alpaugh, Maria Masnata, Aurelie de Rus Jacquet, Eva Lepinay, Hélèna L. Denis, Martine Saint-Pierre, Peter Davies, Emmanuel Planel, Francesca Cicchetti. DOI 10.1016/j.ymthe.2022.01.020

Prompting endogenous repair of brain injury: science fiction or reality? Molecular Neurodegeneration, 2022. de Rus Jacquet, A., Cicchetti, F.. DOI 10.1186/s13024-022-00539-7

A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in ParkinsonAU disease: PleasenotethatParkinsonsdiseasehasbeen PLoS Biology, 2022. Bérard, M., Sheta, R., Malvaut, S., Rodriguez-Aller, R., Teixeira, M., Idi, W., Turmel, R., Alpaugh, M., Dubois, M., Dahmene, M., Salesse, C., Lamontagne-Proulx, J., St-Pierre, M.-K., Tavassoly, O., Luo, W., Cid-Pellitero, E.D., Qazi, R., Jeong, J.-W., Durcan, T.M., Vallières, L., Tremblay, M.-E., Soulet, D., Lévesque, M., Cicchetti, F., Fon, E.A., Saghatelyan, A., Oueslati, A.. DOI 10.1371/journal.pbio.3001578

Sox6 expression distinguishes dorsally and ventrally biased dopamine neurons in the substantia nigra with distinctive properties and embryonic origins. Cell reports, 2021/11/01. DOI 10.1016/j.celrep.2021.109975

Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance. Molecular psychiatry, 2021/10/28. DOI 10.1038/s41380-021-01350-4

Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism & related disorders, 2021/09/01. DOI 10.1016/j.parkreldis.2021.08.018

Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders Molecular Psychiatry, 2021/07. Aurélie de Rus Jacquet, Hélèna L. Denis, Francesca Cicchetti, Melanie Alpaugh. DOI 10.1038/s41380-020-00999-7

Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. Molecular psychiatry, 2021/07/01. DOI 10.1038/s41380-021-01055-8

Huntington's disease: lessons from prion disorders. Journal of neurology, 2021/02/24. DOI 10.1007/s00415-021-10418-8

Correction: Shedding a new light on Huntington’s disease: how blood can both propagate and ameliorate disease pathology (Molecular Psychiatry, (2021), 26, 9, (5441-5463), 10.1038/s41380-020-0787-4) Molecular Psychiatry, 2021. Rieux, M., Alpaugh, M., Sciacca, G., Saint-Pierre, M., Masnata, M., Denis, H.L., Lévesque, S.A., Herrmann, F., Bazenet, C., Garneau, A.P., Isenring, P., Truant, R., Oueslati, A., Gould, P.V., Ast, A., Wanker, E.E., Lacroix, S., Cicchetti, F.. DOI 10.1038/s41380-020-0850-1

Targeting Tau to Treat Clinical Features of Huntington's Disease. Frontiers in neurology, 2020/11/19. DOI 10.3389/fneur.2020.580732

Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases. The Journal of experimental medicine, 2020/09/01. DOI 10.1084/jem.20191430

Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication. Neurobiology of disease, 2020/08/13. DOI 10.1016/j.nbd.2020.105042

Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology. Molecular psychiatry, 2020/06/08. DOI 10.1038/s41380-020-0787-4

Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates. Neurobiology of disease, 2020/05/18. DOI 10.1016/j.nbd.2020.104951

Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of disease, 2020/05/12. DOI 10.1016/j.nbd.2020.104943

Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates. Neurobiology of disease, 2020/05/11. DOI 10.1016/j.nbd.2020.104941

Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology. Journal of neuroinflammation, 2020/04/02. DOI 10.1186/s12974-020-01782-9

The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's disease, 2020/01/01. DOI 10.3233/jpd-191775